

**REMARKS**

Entry of the foregoing and reconsideration of the application identified in caption, as amended, pursuant to and consistent with 37 C.F.R. § 1.114 and in light of the remarks which follow, are respectfully requested.

By the above amendments, claim 32 has been canceled without prejudice or disclaimer. New claims 38-55 have been added which are directed to processes for treating biological targets in a fluid of a biological organism. Support for new claim 38 can be found in the specification at least at page 18, line 9 to page 19, line 4. Support for new claims 39-40 can be found at least in Figure 2. Support for new claims 41-42 can be found at least at page 21, line 18 to page 22, line 2, taken in connection with Figure 4. Support for new claim 43 can be found at least at page 22, lines 9-14, taken in connection with Figure 6. Support for new claims 44-47 can be found at least at page 18, lines 2-14. Support exists for new claims 48-49 at least pages 9 and 10. Support for new claims 50 can be found at least at page 23, line 3-9 taken in connection with Figure 9b. Support for new claims 51-52 can be found at least at page 18, lines 17-20. Support for new claim 53 can be found at least at page 18, lines 13-14. Supports exists for new claim 54 at least at page 18, lines 15-16. Support for new independent claim 55 can be found in the specification at least at page 18, line 9 to page 19, line 4, taken in connection with pages 24-28. Entry of the above amendments is proper at least because a Request for Continued Examination is being filed herewith. See 37 C.F.R. § 1.114.

In the Official Action, claim 32 stands rejected under 35 U.S.C. § 103(a) as being obvious over *Guirguis* in view of U.S. Patent No. 7,006,858 (*Silver et al*). Without addressing the propriety of this rejection, it is noted that such rejection is moot in light of the cancellation of claim 32.

Moreover, Applicants note that applied art of record fails to disclose or suggest each feature recited in newly presented independent claims 38 and 55. For example, the applied art does not disclose or suggest that during flow of the fluid through the flow chamber, the biological target permeates through a permeable member to a capture zone, as recited in independent claim 38. Furthermore, there is no disclosure or suggestion that during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target specific binding agent, as recited in independent claim 55.

From the foregoing, further and favorable action in the form of a Notice of Allowance is believed to be next in order, and such action is earnestly solicited. If there are any questions concerning this paper or the application in general, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: May 29, 2007

By:



Roger H. Lee  
Registration No. 46317

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620